Chemokine Therapeutics to Present Data on its Blood Vessel Regeneration Compound CTCE-0324

24-Jul-2006

Chemokine Therapeutics Corp. will present the blood vessel regeneration effect's of its novel compound CTCE-0324 at the 2006 Gordon Research Conference on Chemotactic cytokines to be held in Aussois, France during September 18-22, 2006.

The Company has developed a new pre-clinical drug candidate that causes blood vessel regeneration once injected locally in the body. In a series of in-vitro and in-vivo experiments, the Company has demonstrated that CTCE-0324 enhances the survival of endothelial cells (essential components of existing blood vessels), stimulates the differentiation of individual endothelial cells into coordinated tube-like structures (mini blood vessels), and induces new blood vessels to sprout from existing ones using cell culture systems. The Company also demonstrated, by way of injection in an animal model, that CTCE-0324 mobilizes stem cells and induces the formation of new blood vessels. This work further underscores the potential of CTCE-0324, thus providing the framework for its continued development as a potential novel therapy for the treatment of vascular diseases.

There are a number of vascular diseases including peripheral and coronary arterial disease affecting approximately 10% of Americans. Currently there is very limited treatment available and often these patients require some form of surgical intervention, including limb amputation or open heart surgery. Collateral blood vessel formation is a natural response to blood vessel blockage, however blood vessel formation is often suboptimal or impaired, especially in the elderly, diabetics, obese and atherosclerosis patients. Therefore, the development of drugs that stimulate new blood vessel growth is of critical importance.

https://www.bionity.com/en/news/56555/chemokine-therapeutics-to-present-data-on-its-blood-vessel-regeneration-compound-ctce-0324.html